<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>▾Exenatide is a glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) <z:chebi fb="4" ids="48705">agonist</z:chebi> used in the management of people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>A twice-daily injectable formulation (▾Byetta - Eli Lilly) was licensed in 2006. ▾Bydureon (Eli Lilly) is a prolonged-release injectable formulation that allows once-weekly administration </plain></SENT>
<SENT sid="2" pm="."><plain>Here we discuss the place of Bydureon in the management of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>